Jeffrey N. Simmons - 01 Mar 2026 Form 4 Insider Report for Elanco Animal Health Inc (ELAN)

Reporting relationship: PRESIDENT, CEO AND DIRECTOR, Director
Issuer ticker: ELAN
Reported as of: 01 Mar 2026
Net transaction value: -$6,071,525
SEC form: 4
Accepted by SEC: 03 Mar 2026, 19:18:37 UTC
Prior SEC filing: 24 Feb 2026
Next SEC filing: 05 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Amy C. Seidel, as Attorney-in-Fact for Jeffrey N. Simmons

Key filing fact

Jeffrey N. Simmons filed Form 4 for Elanco Animal Health Inc (ELAN) on 03 Mar 2026.

Key facts

This page summarizes Jeffrey N. Simmons's Form 4 filing for Elanco Animal Health Inc (ELAN).
5 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 03 Mar 2026, 19:18.

Change

Previous filing in this sequence was filed on 24 Feb 2026.
Current net transaction value: -$6,071,525.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001479079 Primary reporting owner

Simmons Jeffrey N

Relationship: PRESIDENT, CEO AND DIRECTOR, Director
Address: C/O ELANCO ANIMAL HEALTH INCORPORATED, 450 ELANCO CIRCLE, INDIANAPOLIS
Signature: /s/ Amy C. Seidel, as Attorney-in-Fact for Jeffrey N. Simmons
Signature date: 03 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ELAN transaction

Common Stock

Award

Transaction value: $0
Shares: +397,041
Change %: +22%
Price: $0.000000
Shares after: 2,200,459
Date: 01 Mar 2026
Ownership: Direct
Footnotes: F1

ELAN transaction

Common Stock

Tax liability

Transaction value: $6,071,525
Shares: -229,982
Change %: -10%
Price: $26.40
Shares after: 1,970,477
Date: 01 Mar 2026
Ownership: Direct

ELAN transaction

Common Stock

Award

Transaction value: $0
Shares: +119,319
Change %: +6.1%
Price: $0.000000
Shares after: 2,089,796
Date: 01 Mar 2026
Ownership: Direct
Footnotes: F2

ELAN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 167,000
Date: 01 Mar 2026
Ownership: By Revocable Trust

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELAN transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +243,809
Change %
Price: $0.000000
Shares after: 243,809
Date: 01 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 243,809
Exercise price: $26.40
Footnotes: F3

ELAN transaction Derivative

Deferred Stock Units (Match)

Award

Transaction value: $0
Shares: +6,593
Change %
Price: $0.000000
Shares after: 6,593
Date: 01 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,593
Exercise price
Footnotes: F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Includes 1,038 shares acquired on January 31, 2026 under Elanco Animal Health Inc.'s Employee Stock Purchase Plan.

Footnote F2

Grant of restricted stock units vesting as follows: one-third vesting on March 1, 2027, one-third vesting on March 1, 2028, and the remaining vesting on March 1, 2029.

Footnote F3

Grant of stock options vesting as follows: one-third vesting on March 1, 2027, one-third vesting on March 1, 2028, and the remaining vesting on March 1, 2029.

Footnote F4

Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.

Footnote F5

Deferred stock units vest December 31, 2027 and settle upon termination of employment or otherwise in accordance with the Executive Deferral and Stock Match Plan.